Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

148.14
+1.841.26%
Volume:692.69K
Turnover:102.04M
Market Cap:183.79B
PE:-56.65
High:148.16
Open:146.58
Low:146.12
Close:146.30
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.62
T/O Rate:0.06%
Dividend:3.22
Dividend Rate:2.17%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.54
PE(LYR):21.85

Loading ...

Gilead - Expands Six Royalty-Free Voluntary Licensing Agreements for Once-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS
·
2 hours ago

The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.

Dow Jones
·
3 hours ago

Rohto Starts Phase II Trial of RE-01 Cell Therapy for Refractory Ischemic Leg Ulcers

Reuters
·
11 hours ago

Gilead Sciences Expands Lenacapavir Access to 14 Countries

MT Newswires Live
·
Yesterday

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Yesterday

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Yesterday

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Yesterday

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Yesterday

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Yesterday

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Yesterday

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

Dow Jones
·
Sep 12

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

TIPRANKS
·
Sep 11

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09